LIVER DISEASE

Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis

M Longo, A Crosignani, P M Battezzati, C Squarcia Giussani, P Invernizzi, M Zuin, M Podda

Division of Internal Medicine, Department of Medicine, Surgery, and Dentistry, San Paolo School of Medicine, University of Milan, Italy

Correspondence to:
Correspondence to:
Dr M Podda, Division of Internal Medicine, Department of Medicine, Surgery, and Dentistry, San Paolo School of Medicine, Via Di Rudinì 8, 20142 Milano, Italy;
mauro.podda{at}unimi.it

Background: Primary biliary cirrhosis (PBC), a chronic cholestatic liver disease, is frequently associated with severe hypercholesterolaemia but the clinical significance of this finding is unclear.

Aims: To characterise changes in serum lipid profile over time and to assess the risk of cardiovascular disease in PBC.

Subjects and methods: We studied a cohort of 400 PBC patients for 6.2 years (range 4 months to 24 years) by serial determinations of serum lipid levels and registration of all cardiovascular events. Subjects included in an Italian prospective population based study served as controls.

Results: At presentation, 76% of patients had serum cholesterol levels >5.2 mmol/l. Hyperbilirubinaemic patients had higher total cholesterol and lower high density lipoprotein (HDL) cholesterol levels (p<0.001). With time, disease progression was associated with a reduction in total (p<0.001) and HDL (p<0.05) cholesterol. The incidence of cardiovascular events was similar to that of the general population (cerebrovascular events: standardised ratio 1.4; 95% confidence interval 0.5–3.7; coronary events: 2.2; 0.9–4.3). Hypertension was associated with an increased risk of cardiovascular events (3.8; 1.6–8.9). Association with moderate hypercholesterolaemia was of borderline significance (3.8; 0.9–17) whereas severe hypercholesterolaemia was not associated with increased risk (2.4, 0.5–11).

Conclusions: In PBC, serum cholesterol levels markedly increase with worsening of cholestasis, and decrease in the late disease stages, despite a severe reduction in biliary secretion. Marked hypercholesterolaemia, typical of severe longstanding cholestasis, is not associated with an excess risk of cardiovascular disease while less advanced patients with moderate hypercholesterolaemia are exposed to an increased cardiovascular risk. Putative protective factors in PBC patients with severe hypercholesterolaemia should be assessed.

Keywords: primary biliary cirrhosis; hypercholesterolaemia; cholesterol; cardiovascular disease

Abbreviations: PBC, primary biliary cirrhosis; HDL, high density lipoprotein; LDL, low density lipoprotein; UDCA, ursodeoxycholic acid

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Digest

Ian Forgacs
Gut 2002 51: 143. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Lindor, K. (2007). Ursodeoxycholic Acid for the Treatment of Primary Biliary Cirrhosis. NEJM 357: 1524-1529 [Full Text]  
• Allocca, M, Crosignani, A, Gritti, A, Ghilardi, G, Gobatti, D, Caruso, D, Zuin, M, Podda, M, Battezzati, P M (2006). Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 55: 1795-1800 [Abstract] [Full Text]  
• Jones, D E J, Bhala, N, Burt, J, Goldblatt, J, Prince, M, Newton, J L (2006). Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 55: 536-541 [Abstract] [Full Text]  
• Kaplan, M. M., Gershwin, M. E. (2005). Primary Biliary Cirrhosis. NEJM 353: 1261-1273 [Full Text]  
• Stedman, C. A. M., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G. A., Moore, D. D., Evans, R. M., Downes, M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc. Natl. Acad. Sci. USA 102: 2063-2068 [Abstract] [Full Text]  
• Prince, M I, Chetwynd, A, Craig, W L, Metcalf, J V, James, O F W (2004). Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 53: 865-870 [Abstract] [Full Text]  
• Guo, G. L., Lambert, G., Negishi, M., Ward, J. M., Brewer, H. B. Jr., Kliewer, S. A., Gonzalez, F. J., Sinal, C. J. (2003). Complementary Roles of Farnesoid X Receptor, Pregnane X Receptor, and Constitutive Androstane Receptor in Protection against Bile Acid Toxicity. J. Biol. Chem. 278: 45062-45071 [Abstract] [Full Text]